Skip to main content

Drug Safety

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

GLP-1 Therapy in Knee Osteoarthritis

Apr 08, 2021

Knee osteoarthritis is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable. The use of anti-diabetic glucagon-like peptide-1 therapies have demonstrated significant weight loss benefits; hence this trial evaluated the potential weight loss and

Read Article

Implementing Smoking Cessation Programs

Apr 07, 2021

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

Reactogenicity Following mRNA COVID-19 Vaccines

Apr 06, 2021

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article

Rituximab in Systemic Sclerosis?

Apr 05, 2021

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Apr 01, 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.



Janus kinase

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article
Have you listened to this week's podcast? Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow. Download wherever podcasts are available. https://t.co/Twy04G9RU1 https://t.co/NSsR2tFq5i
Dr. John Cush @RheumNow( View Tweet )
Mar 31, 2021
From @KDAO2011 for #RNL2021 Is it better to taper the steroids or leave it? SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects. Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less) https://t.co/FpQnxUKWwF

Dr. John Cush @RheumNow( View Tweet )

Mar 30, 2021
News Feature: Serious Infections Still Common in Vasculitis Serious infections occurred more frequently among patients with ANCA-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan). #RheumNow https://t.co/dTL6cReg8s https://t.co/U2sbEzd5DX
Dr. John Cush @RheumNow( View Tweet )
Mar 30, 2021

Serious Infections Still Common in Vasculitis

MedPage Today
Mar 29, 2021

Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.

Read Article
RheumNow Podcast – Infection in ANCA-Associated Vasculitis Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on https://t.co/4GKxMY5Lll https://t.co/joi1puBSuX

Dr. John Cush @RheumNow( View Tweet )

Mar 26, 2021

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Mar 26, 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.




  1. Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Read Article
News Feature: Safety of Paternal DMARD or Biologic Use https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
Dr. John Cush @RheumNow( View Tweet )
Mar 25, 2021
Retrospective study of 162 ANCA-Assoc Vasculitis patients (63% GPA, 37% MPA) - risk of serious infx was 7.5 per 100Pt-Yrs & was higher with cyclophosphamide that RTX induction. Risks for SIE:plasmapheresis dialysis & high BVAS in 1st year https://t.co/kAlz9aGQup

Dr. John Cush @RheumNow( View Tweet )

Mar 25, 2021
Biologic efficacy in 147 pts w/ eosinophilic granulomatosis with polyangiitis - compares RTX (63), mepolizumab (51) or omalizumab (31). Remission/partial rates were better in RTX (49%/24%) and MEPO (78%, 10%) vs OMA (15%/33%) https://t.co/ZsCFVnasIJ

Dr. John Cush @RheumNow( View Tweet )

Mar 24, 2021
Uveitis is uncommonly caused drugs - especially : bisphosphonates, immune checkpoint inhibitors and antiviral drugs. https://t.co/hWO3QFcuMb

Dr. John Cush @RheumNow( View Tweet )

Mar 24, 2021

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

Mar 24, 2021

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA. Several noteworthy ones were

Read Article

Safety of Paternal DMARD or Biologic Use

Mar 22, 2021

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

Mar 22, 2021

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Read Article

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

Mar 22, 2021

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr. Stanley Cohen detailed many issues

Read Article
New podcast available! Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow. https://t.co/rPnLp2NfRq https://t.co/TSTP2tWxXy
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2021
News Feature: Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures https://t.co/KazNPRXKNx https://t.co/pykBdbexzF
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2021
×